Metagelan (Metamizole Sodium Monohydrate)

Metamizole sodium acts by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces peripheral pain signalling. It also has central analgesic effects that are not fully understood, contributing to its antipyretic and analgesic actions.

The specific dose of Metagelan is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for metamizole sodium during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Metagelan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metagelan (metamizole) differs from traditional NSAIDs such as ibuprofen or diclofenac by having a distinct pyrazolone structure and a lower incidence of gastrointestinal irritation. Compared with paracetamol, it often provides stronger analgesia for severe pain but carries a rare risk of agranulocytosis, requiring careful monitoring.

Metagelan should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Metagelan is taken orally, usually with a glass of water. It can be taken with or without food, but patients who experience stomach upset may prefer to take it with a meal. The tablet should be swallowed whole and not chewed or crushed.

The most serious adverse reactions to Metagelan include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, fever, or allergic symptoms and seek immediate medical attention if they occur.

Metagelan is contraindicated in individuals with known hypersensitivity to metamizole or other pyrazolone derivatives. It should also be avoided in patients with a history of severe blood dyscrasias, uncontrolled hypertension, or those currently receiving bone‑marrow‑suppressive therapy.